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Early Th2 inflammation in the upper respiratory mucosa as
a predictor of severe COVID-19 and modulation by early
treatment with inhaled corticosteroids: a mechanistic
analysis
Jonathan R Baker, Mahdi Mahdi, Dan V Nicolau Jr, Sanjay Ramakrishnan, Peter J Barnes, Jodie L Simpson, Steven P Cass, Richard E K Russell,
Louise E Donnelly, Mona Bafadhel

Summary

Background Community-based clinical trials of the inhaled corticosteroid budesonide in early COVID-19 have shown
improved patient outcomes. We aimed to understand the inflammatory mechanism of budesonide in the treatment
of early COVID-19.
Methods The STOIC trial was a randomised, open label, parallel group, phase 2 clinical intervention trial where
patients were randomly assigned (1:1) to receive usual care (as needed antipyretics were only available treatment)
or inhaled budesonide at a dose of 800 μg twice a day plus usual care. For this experimental analysis, we investigated
the nasal mucosal inflammatory response in patients recruited to the STOIC trial and in a cohort of SARS-CoV-2negative healthy controls, recruited from a long-term observational data collection study at the University of
Oxford. In patients with SARS-CoV-2 who entered the STOIC study, nasal epithelial lining fluid was sampled at
day of randomisation (day 0) and at day 14 following randomisation, blood samples were also collected at day 28
after randomisation. Nasal epithelial lining fluid and blood samples were collected from the SARS-CoV-2 negative
control cohort. Inflammatory mediators in the nasal epithelial lining fluid and blood were assessed for a range of
viral response proteins, and innate and adaptive response markers using Meso Scale Discovery enzyme linked
immunoassay panels. These samples were used to investigate the evolution of inflammation in the early COVID-19
disease course and assess the effect of budesonide on inflammation.
Findings 146 participants were recruited in the STOIC trial (n=73 in the usual care group; n=73 in the budesonide
group). 140 nasal mucosal samples were available at day 0 (randomisation) and 122 samples at day 14. At day 28, whole
blood was collected from 123 participants (62 in the budesonide group and 61 in the usual care group).
20 blood or nasal samples were collected from healthy controls. In early COVID-19 disease, there was an enhanced
inflammatory airway response with the induction of an anti-viral and T-helper 1 and 2 (Th1/2) inflammatory response
compared with healthy individuals. Individuals with COVID-19 who clinically deteriorated (ie, who met the primary
outcome) showed an early blunted respiratory interferon response and pronounced and persistent Th2 inflammation,
mediated by CC chemokine ligand (CCL)-24, compared with those with COVID-19 who did not clinically deteriorate.
Over time, the natural course of COVID-19 showed persistently high respiratory interferon concentrations and elevated
concentrations of the eosinophil chemokine, CCL-11, despite clinical symptom improvement. There was persistent
systemic inflammation after 28 days following COVID-19, including elevated concentrations of interleukin (IL)-6,
tumour necrosis factor-α, and CCL-11. Budesonide treatment modulated inflammation in the nose and blood and was
shown to decrease IL-33 and increase CCL17. The STOIC trial was registered with ClinicalTrials.gov, NCT04416399.
Interpretation An initial blunted interferon response and heightened T-helper 2 inflammatory response in the
respiratory tract following SARS-CoV-2 infection could be a biomarker for predicting the development of severe
COVID-19 disease. The clinical benefit of inhaled budesonide in early COVID-19 is likely to be as a consequence of its
inflammatory modulatory effect, suggesting efficacy by reducing epithelial damage and an improved T-cell response.
Funding Oxford National Institute of Health Research Biomedical Research Centre and AstraZeneca.
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
Understanding of the inflammation that occurs following
SARS-CoV-2 infection has increased.1 Mainly, the immune
response in patients with severe infection who require
hospitalisation has been investigated.2 The early COVID-19
www.thelancet.com/respiratory Vol 10 June 2022

studies focused on inflammation caused by the systemic
immune response3 whereas the inflammatory response in
the airway of patients remains largely unknown, in part
because of the risk of contagion through aerosolisation of
the virus. The airway inflammatory response to common
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Research in context
Evidence before this study
Almost all patients with COVID-19 have an early prodromic illness
and some develop severe COVID-19 illness requiring hospital care.
There is a widespread view that the symptoms in early COVID-19
reflect a viral replication phase, whereas the severe hospitalised
phase of the illness reflects an inflammatory phase of COVID-19.
We searched PubMed with search terms “early COVID-19”,
“SARS-CoV-2”, “respiratory inflammation”, “inhaled steroids”,
“mechanism”, and “clinical trials”, from database inception to
July 19, 2021, for studies published in English. Two community
based randomised clinical trials (STOIC and PRINCIPLE) have
shown that treating patients within 7 or 14 days of symptom
onset with inhaled budesonide reduced the time to symptom
resolution and reduced the risk of increase health-care resource
utilisation. The early respiratory inflammatory manifestation
following SARS-CoV-2 virus infection and mechanism of efficacy
of inhaled budesonide is unknown.

T-helper 2 (Th2) lymphocyte pathways. In patients with
COVID-19 not treated with budesonide, there was persistently
raised interferon and eosinophil chemokines. Interestingly,
in patients with COVID-19 who met the primary endpoint
(ie, clinical deterioration measured by urgent care visits), there
was a muted early inflammatory response, except for raised
eosinophil chemokines, followed by a severe second peak of
inflammation. Budesonide treatment attenuated the
eosinophil chemokine-driven inflammation, reduced the peak
of the interferon and Th1 and Th2 lymphocyte-related
inflammatory pathways, in addition to modulating
inflammation in the respiratory tract and in the circulation.
To our knowledge, this is the first study on the nasal mucosa
and inflammatory markers in early disease and the first to
investigate the mechanism of treatments used to treat
COVID-19, which has determined potential biomarkers that
can predict worsening COVID-19.

Added value of this study
To our knowledge, the STOIC study is the only study to have
sampled the nasal mucosa in early COVID-19, both at the early
stages of the illness and following 2 weeks of study follow-up.
Sampling was done routinely and prospectively on all trial
participants, avoiding any sampling bias. Contrary to the
prevailing view that inflammation occurs in the later, more
severe stage of disease, there is a marked inflammation in the
airway in early COVID-19. This effect was observed across viral
response proteins, and T-helper 1 (Th1) lymphocyte and

Implication of the all the available evidence
Many drugs were repurposed during the COVID-19 pandemic.
Although some of these medications have been shown to be
effective, there is little known about the mechanistic mode of
action. This study provides further scientific validity to the
STOIC trial, with prospectively and longitudinally collected
airway samples showing that inhaled budesonide effectively
altered the airway mucosal and the systemic inflammatory
pattern. Inhaled corticosteroids are therefore efficacious in
treating early COVID-19.

respiratory viruses in healthy individuals4 and in patients
with chronic airways disease has been extensively
studied.5,6 Inhaled corticosteroids are often prescribed in
patients with asthma and chronic obstructive pulmonary
disease (COPD) to reduce the risk of exacerbations, which
are usually mediated by respiratory viruses.7–9 During the
ongoing COVID-19 pandemic, it has been reported that
patients with asthma and COPD are less likely to be
hospitalised with severe COVID-19 than people with
comorbidities (eg, cardiovascular, diabetes, hypertension,
and obesity).10,11 The reasons for this observation are
unclear but, in patients with asthma, the use of inhaled
corticosteroids 2 weeks before hospitalisation for severe
COVID-19 was associated with better clinical outcomes.12
Our recent STOIC study13 investigated inhaled budesonide,
a corticosteroid, as a treatment for early SARS-CoV-2
infection with positive findings in improvement of selfreported symptom recovery, with fewer patients
experiencing adverse outcomes and less symptom
persistence. This finding was replicated in a large phase 3
efficacy trial (PRINCIPLE),14 but has yet to be adopted
globally. The mechanism for how inhaled corticosteroids
can improve early COVID-19 is currently unknown.
Here, we report the nasal mucosal inflammatory
response in patients with early COVID-19 disease and
examine the evolution of inflammation in the natural
546

course of COVID-19 in patients from the STOIC study.
We also identify how inflammation in the airway can
predict illness severity and investigate the effect of
inhaled budesonide on the respiratory mucosa in early
COVID-19 disease. Finally, we show, by use of network
analysis, how inhaled budesonide can resolve the
exaggerated inflammatory response observed in early
SARS-CoV-2 infection and aim to restore health.

Methods

Study design and participants
In this experimental analysis, we report on measures of
inflammation using nasal mucosal lining fluid samples
and serum samples collected during the STOIC trial.
STOIC was a randomised, open-label, parallel group,
phase 2 clinical intervention trial, which has been
previously published.13 In brief, participants aged 18 years
or older with early COVID-19 symptoms (defined as new
onset of cough, fever, anosmia, or a combination of these
symptoms for less than 7 days) were randomly
assigned (1:1) to receive usual care (as needed antipyretics)
or inhaled budesonide at a dose of 800 μg twice a day plus
usual care. Participants were seen by nurses at home at
randomisation (day 0) and day 14, when self-performed
nasosorption was collected. At day 28, whole blood was
collected. Full details of the study design can be found in
www.thelancet.com/respiratory Vol 10 June 2022
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the appendix (p 4). Participants provided written informed
consent. The STOIC study was approved by the Fulham
London Research Ethics Committee (20/HRA/2531) and
the National Health Research Authority.
Healthy controls were adults aged 18 years or older
without any known history of lung disease or COVID-19
symptoms (including negative COVID-19 antigen tests
done on the day of nasal epithelial lining fluid and blood
sampling), recruited from a long-term observational
data collection study at the University of Oxford (ethics
reference 18/SC/0361). Healthy controls were used as a
comparator to evaluate inflammation in the healthy
upper respiratory tract.

Procedures
For this experimental analysis, nasal mucosal lining fluid
was collected at days 0 and day 14 after randomisation
with a nasosorption FX.I device (Hunt Developments UK,
London, UK), consisting of a synthetic absorptive matrix
strip against the inferior turbinate, for 1 min. Whole blood
was collected at day 28 after randomisation and was
allowed to clot for 60 min at room temperature. RNA was
extracted using the QIAamp Viral RNA Mini Kit (Qiagen,
MD, USA) following manufacturer’s instructions, and
testing for SARS-CoV-2 infection was done by quantitative
real-time RT-PCR. Full details of sample collection and
processing is in the appendix (p 1).
Immunoassays of mediators were selected to represent
putative mechanistic inflammatory pathways associated
with respiratory virus infections, and thus COVID-19,15–17
and were quantified using MSD (Meso Scale Diagnostics,
Rockville, MD, USA). All values at or below the lower
limit of detection (LLOD) or above the upper limit of
detection (ULOD) were replaced by the LLOD or ULOD
value as suggested by the assay parameters and are
shown in the appendix (p 16). The mediator transforming
growth factor beta-1 (TGFB1) was not done in the control
samples because of assay unavailability.

Outcomes
We investigated the nasal mucosal inflammatory
response in patients with early COVID-19 disease from
samples collected in the STOIC study at an early
timepoint of disease onset (ie, within 7 days of
symptoms) and compared it with the nasal mucosal
inflammatory response in healthy controls. We also
assessed the natural course of inflammatory response by
evaluating resolution of inflammation in participants of
the STOIC study comparing inflammation at an early
timepoint and 14 days after study randomisation. Our
analysis provides insight of mucosal inflammation
following SARS-CoV-2 infection, which is predictive of
worsening of COVID-19 illness. Finally, we studied the
effect of treatment with inhaled budesonide on nasal
mucosal inflammation compared with usual care and
determined how budesonide resolves the exaggerated
inflammatory response.
www.thelancet.com/respiratory Vol 10 June 2022

Statistical analysis

See Online for appendix

To illustrate the temporal trends in inflammatory
mediator concentrations in the usual care and
budesonide study groups, we plotted smoothed splines
of longitudinal mediator concentration data, using raw
pg/mL data and the date from which symptoms started.
This spline best-fit curve analysis assesses kinetic
inflammatory changes over the disease course of early
COVID-19 disease (represented in this study by the usual
care study group) and with inhaled corticosteroids
intervention (budesonide study group). Spline analysis
considers the timing of the first symptom and gives an
indication of peak of inflammation and resolution. The
spline analysis was performed on all inflammatory
mediators. Heatmaps were drawn to visualise data as a
magnitude of change of all inflammatory mediators
between healthy controls, early COVID-19 disease (day
0), and longitudinal (day 14) follow-up in usual care and
budesonide treatment study groups. Inflammatory
mediator data were standardised between mediators by
calculating Z scores (using mean and SD from raw
mediator values [pg/mL]).18
Volcano plots were drawn to illustrate in a scatterplot
the magnitude of change (fold change, x-axis), against the
statistical significance of that change (log10 of p value,
y-axis). These were drawn for all mediators against the
following conditions: comparison of inflammation in
health and early COVID-19 (healthy controls against
early COVID-19); the evolution of inflammation in the
usual care study group (day 0 and day 14); the evolution
of inflammation in the budesonide study group (day 0
and day 14); and comparison of day 0 inflammation in
patients that deteriorated with COVID-19 (reaching
primary endpoint) compared with those who did not
deteriorate. Mann-Whitney or Wilcoxon signed-rank test
was performed for unpaired or paired analysis for the
magnitude of change. Serum samples were analysed
with the Kruskall-Wallis test with post-hoc Dunn’s
multiple comparison test performed on all mediators.
To further elucidate the patterns of interactions between
all inflammatory mediators in COVID-19 in the usual
care and budesonide study groups, network analysis and
visualisation software were developed in-house using
MATLAB version 2021. We studied correlation matrices
of mediator responses across the study groups, removing
the noise eigenvalues and thus building up error-free
mediator–mediator interaction networks. We then
analysed these matrices to find modules of mediators that
are interconnected with each other and relatively
unconnected to other modules.
p values of less than 0·05 were considered statistically
significant. All statistical analyses used GraphPad Prism
version 9.0.0 and MATLAB version 2021. Full details of
the network statistical analysis are presented in the
appendix (p 2).
The STOIC trial was registered with ClinicalTrials.gov,
NCT04416399.
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Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report.

Results
The STOIC study recruited 146 participants aged
18–79 years (mean 45 years [SD 13]) with a median
duration of COVID-19 symptoms of 3 days (IQR 2–5).
140 nasal mucosal samples were available at day 0
(randomisation, visit 1) and 122 samples after 14 days
(visit 3). At day 28 (visit 4), whole blood was collected from
123 participants (62 in the budesonide group, 61 in the
usual care group). The healthy control cohort consisted
of 20 samples from 20 healthy individuals. The
demographics of the healthy volunteers and COVID-19
STOIC participants are presented in the appendix (p 15).
Time to self-reported clinical recovery for all participants
in the STOIC study was a mean of 9 days (SD 6).
We examined the inflammatory profile of nasal
mucosal fluid in healthy controls and early COVID-19
(figure 1A). We found that 16 mediators were increased
in all patients infected with COVID-19 in both treatment
groups compared with controls. These mediators were
T-helper-type 1 (Th1) cytokines (interleukin [IL]-2, IL-12,
tumour necrosis factor [TNF]-α, and IL-6,), T-helpertype 2 (Th2) cytokines (IL-4), interferon response proteins
(interferon [IFN]-α2a, IFN-β, IFN-γ, CXC chemokine
(CXC)L10, CXCL9, and CXCL11), and other chemokines
(CC chemokine ligand (CCL)3, CCL4, CCL5, CCL11, and
CCL13; figure 1B). An altered T-cell response with
statistically significantly reductions in concentrations of
thymic stromal lymphopoietin (TSLP) and CCL17 was
also found in these patients; CCL2 concentrations were
also decreased, related to impaired monocyte recruitment
(figure 1B). Patients with COVID-19 also had lower
concentration of vascular endothelial growth factor
(VEGF; figure 1B). Some mediators were unaltered
(IL-1β, IL-33, CCL24, CCL26, IL-5, granulocyte-macro
phage colony-stimulating factor [GM-CSF], and IL-10;
figure 1B), highlighting less activation during early
COVID-19. CXCL8 was unchanged between health and
early COVID-19.
We examined nasal mucosal inflammation during the
course of disease (ie, in the usual care group), examining
paired samples from the usual care group population at
day 0 and day 14 (n=60; figure 1C). Over the course of
14 days, concentrations of CXCL9, CXCL10, CXCL11,
IL-12, IL-10, IL-2, IFN-α2a, CCL2, CCL3, CCL4, IL-6, IL-4,
CCL13, and TNF-α statistically significantly decreased. Of
the 16 mediators elevated in early COVID-19 compared
with healthy controls, 11 decreased over time (CCL3,
CCL4, TNF-α, IL-6, CCL13, IL-4, IFN-α2a, CXCL10,
CXCL11, IL-2, and IL-12). CCL11, IFN-β, and IFN-γ did
not significantly change between day 0 and day 14 and
remained elevated after 14 days in patients with COVID-19
in the usual care group compared with healthy volunteers.
548

VEGF, TSLP, and CCL17 concentrations were unchanged
over time in patients with COVID-19, remaining lower
than those measured in healthy volunteers, but CCL2 and
IL-10 concentrations significantly reduced further
compared with day 14 (figure 1C and figure 1D). IL-1β,
CXCL8, IL-33, CCL24, CCL26, IL-5, and GM-CSF did not
show any changes between the two study visits over time.
To investigate the potential mechanisms of how
budesonide reduces time to clinical recovery in patients
with COVID-19, we examined the concentrations of
30 mediators in paired day 0 and day 14 samples in the
inhaled budesonide group of the STOIC trial (n=62,
figure 1E). Of the mediators examined, those that were
different to the natural course of early COVID-19 disease
(as described for the usual care group), IL-33 and IFN-γ
were significantly reduced, CCL17 concentrations were
significantly increased, and CCL13 was no longer signif
icantly reduced between the two visits (figure 1F). The
delta change between paired visits in the usual care study
group and the budesonide study group showed that
budesonide treatment significantly reduced IL-33 and
IFN-γ with increased concentrations of CCL17, whereas
CCL13 was no longer significantly reduced (additional
data in appendix p 5). As all day 0 samples were obtained
before randomisation to the study groups, we also
compared both the usual care group and budesonide
group day 14 samples with all day 0 samples to assess the
return to health. We found that, following treatment with
inhaled budesonide, CCL5 was significantly reduced, but
not GM-CSF; concentrations of IL-2 and IL-4 were
sustained (ie, did not decrease), despite decreasing in the
usual care group (appendix pp 6–8). As the median time
to clinical recovery was 1 day shorter in the budesonide
study treatment group than in with the usual care study
treatment group, these changes in the concentrations of
these mediators might explain differences in the recovery
and the part played in the disease course of COVID-19.
SARS-CoV-2 viral load and nasal mucosal mediator
measurements were available in 122 paired samples at
randomisation (day 0). We found that IFN-α2a, CXCL10,
CXCL11, IL-12, CCL2, and IL-6 correlated with viral load
(appendix p 17).
To assess whether the inflammation associated with
SARS-CoV-2 infection declined over time to concen
trations similar to healthy individuals, we compared our
healthy cohort to the day 14 samples of the usual care and
budesonide study groups (figure 2A). In both usual care
and budesonide groups, compared with healthy controls,
IL-2, CCL11, IL-4, TNF-α, IFN-β, IFN-γ, and CXCL11
remained significantly elevated over time, whereas CCL3,
CCL4, IL-6, CCL13, IFN-α2a, CXCL11, and IL-12 reduced
to comparable healthy concentrations (figure 2B). CCL2
and TSLP remained significantly lower in both study
groups than in healthy volunteers. The concentration of
CCL17 was increased in the budesonide study group over
time and did not return to healthy concentrations. IL-10
significantly decreased over time in the usual care study
www.thelancet.com/respiratory Vol 10 June 2022
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Figure 1: Immunological
features of the nasal mucosa
in patients with early
COVID-19 over time in the
STOIC study
A) Heatmap and B) volcano
plot of 26 nasal mediators
from 20 healthy individuals
and 140 patients with
community-based early
COVID-19. C) Heatmap and
D) volcano plot of 30 nasal
mediators from patients with
community based early
COVID-19 at day 0 after
enrolment in the trial and
day 14 in the usual care group
(n=60). E) Heatmap and
F) volcano plot of
30 nasal mediators from
patients with community
based COVID-19 at
days 0 and 14 in the
budesonide group (n=62).
Horizontal dotted line on
volcano plots depicts the cutoff
for statistical significance; the
vertical dotted line represents
the cutoff point determining
whether mediator
concentrations were higher
significantly (right, red) or
lower (left, blue) for day 14
samples compared with either
healthy controls (unpaired) or
paired day 14 samples.
Black dots represent changes in
mediator concentration. Data
were analysed using MannWhitney t-test or Wilcoxon
matched pairs signed rank test.
IL=interleukin. TNF=tumour
necrosis factor. IFN=interferon.
TSLP=thymic stromal
lymphopoietin. CXCL=CXC
chemokine ligand.
CCL=CC chemokine ligand.
GM-CSF=granulocytemacrophage colonystimulating factor.
VEGF=vascular endothelial
growth factor. PDGF=plateletderived growth factor.
TGF=transforming growth
factor.
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group but not in the budesonide study group (figure 2B),
indicating a sustained anti-inflammatory response in
patients treated with inhaled budesonide.

In general, temporal trends in mediator concentrations
in each group showed that peak inflammation occurred
early in the disease course (figures 2C–E, appendix p 9).
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Figure 2: Temporal changes in
mediator concentrations in
the usual care and
budesonide groups
A) Heatmap of 26 nasal
mediators from 20 healthy
individuals compared with
samples at day 14 after
recruitment (day 14) in the
usual care group (n=60) and
the budesonide group
(n=62). B) List of significantly
altered mediators compared
with healthy controls at day 14
in both usual care and
budesonide groups.
C–E) Longitudinal analysis of
mediator profiles in the usual
care and budesonide groups
displayed as representative
best fit curves by smoothed
spline analysis. Additional data
are presented in appendix
(p 9). IL=interleukin.
TNF=tumour necrosis factor.
IFN=interferon. TSLP=thymic
stromal lymphopoietin.
CXCL=CXC chemokine ligand.
CCL=CC chemokine ligand.
GM-CSF=granulocytemacrophage colonystimulating factor.
VEGF=vascular endothelial
growth factor. PDGF=plateletderived growth factor.
TGF=transforming growth
factor.
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Figure 3: Alterations in nasal mucosal inflammation in patients with early
COVID-19 who clinically deteriorate
A) Volcano plot of 26 nasal mediators from 20 healthy individuals and
11 patients who met the primary outcome of the study. Red dots represent
significantly increased mediator concentrations, blue dots sifnificantly
decreases, and black dots no changes. B–G) Significantly altered mediators at
day 0 from patients with early COVID-19 (n=129) and those who met the
primary outcome (n=11). B) GM-CSF. C) IL-10. D) IL-12. E) IL-2. F) IFN-α2a.
G) IL-33. H) Comparison table of significantly altered mediators from nasal
samples comparing healthy volunteers (n=20) and patients with early COVID-19
(n=129) without deterioration and with COVID-19 with deterioration (n=11).
I) Change in concentrations of 30 mediators from day 0 to day 14 of 1 patient
who required critical care respiratory support (see appendix p 12 for heatmap).
Data were analysed using Mann-Whitney t-test. IL=interleukin. TNF=tumour
necrosis factor. IFN=interferon. TSLP=thymic stromal lymphopoietin.
CXCL=CXC chemokine ligand. CCL=CC chemokine ligand. GM-CSF=granulocytemacrophage colony-stimulating factor. VEGF=vascular endothelial growth
factor. PDGF=platelet-derived growth factor. TGF=transforming growth factor.
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Additionally, IL-4, IL-12, IL-2, CXCL10, platelet derived
growth factor subunit A (PDGFA), and IFN-α2a kinetic
changes were similar between the natural course of early
COVID-19 and inhaled budesonide. However, inhaled
budesonide supressed kinetic inflammation and in
particular a secondary increase in inflammation beyond
day 15 (as seen with TNF-α, GM-CSF, and CCL5). IFN-γ
increased following inhaled budesonide at day 15.
11 participants met the primary outcome for deterioration
in the STOIC clinical trial (defined as needing urgent care
assessment, emergency care consultation, hospitalisation,
or a combination of these outcomes), with 70% needing
oxygen treatment. In comparison with healthy individuals,
participants with early COVID-19 who met the primary
outcome (ten in the usual care group and one in the
budesonide group) had an increase of CCL3, CCL5, TNF-α,
IFN-α2a, IFN-β, CXCL10, CXCL11, CCL11, and CCL24, but
a reduction of CCL2, TSLP, CCL17, IL-10, GM-CSF,
CXCL9, and IL-33 (figure 3A). However, there was an
initial differential mediator response in participants who
deteriorated compared with those who did not deteriorate
following SARS-COV-2 infection. Firstly, there was no
increase in CCL4, IL-12, IFN-γ, IL-4, CCL13, IL-2, and IL-6
in patients who deteriorated (figure 3H), showing an
impaired inflammatory response. Secondly, there was a
reduction in IL-10, IL-33, and GM-CSF in the primary
outcome group. Finally, CCL24 concentrations were
increased in participants who met the primary outcome,
confirming that a high eosinophilic phenotype is associated
with severe disease. Specifically, in participants who had
clinical deterioration, the time course spline analysis
showed that there was an aberrant immune response
during the early part of SARS-CoV-2 infection (appendix
pp 10–11), with significant downregulation of GM-CSF,
IL-10, IL-12, IL-2, IFN-α2a, and IL-33 (figure 3B–G),
suggesting a blunted early response to infection occurs in
patients who then deteriorate. In one participant, who
needed critical care support (usual care study group),
longitudinal nasal sampling was available giving insight
into course of the disease in a more severe patient. The
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mediators included higher concentrations of TNF-α,
CXCL8, and the family of eosinophil chemotactic
proteins (CCL11, CCL24, CCL26). This systemic
inflammation was supressed to a greater degree by
inhaled budesonide for CCL11, TNF-α, and IL-33.
Network analysis of inflammatory mediators in the
nasal mucosa and serum showed an anti-inflammatory
response (IL-10 upregulation) and T2 inflammatory
(CCL11 and CCL24 upregulation) response with coexistent inflammation (upregulation of IL-6 and CXCL8)
in early COVID-19 (figure 5A-1). 2 weeks after initial
infection, the natural course of COVID-19 shows
persistent nasal mucosal inflammation with an
exaggerated T2 inflammatory response (CCL11 and IL-5)
and a sustained pro-inflammatory response (figure 5A-2).
In the usual care study group, network analysis showed a
72% overlap between the inflammatory response during
the first 7 days of COVID-19 symptom onset and at day 14
after randomisation, indicating persistent inflammation
of similar immune pathways. Following inhaled
budesonide treatment, the nasal mucosal response is
different with an increased anti-inflammatory response
(IL-10) and alarmins (IL-33 and TSLP), but a reduced
T2 inflammatory response highlighting normalisation of
the anti-viral immune response and the T2 hyperinflammatory response. The overlap between the
inflammatory response at an early timepoint in COVID-19
and at the later timepoint was only 27% in the budesonide
study group (figure 5A-3). Network analysis of serum
mediators performed between 28 and 35 days after initial
infection in the usual care study group shows persistent
IFN-α2a, CCL11, and CCL2 (figure 5B-1). There was only a
30% overlap with the serum of participants that had been
treated with inhaled budesonide (figure 5B-2) again
indicating immunomodulation.

B

Figure 4: Persistence of systemic inflammation following 28–35 days of COVID-19 in the community
Violin plots comparing some mediator concentrations in the serum of healthy individuals (n=20), those in the
usual care group (n=61), and those in the budesonide group (n=62) of the study at 28–35 days following COVID-19
(see appendix p 13 for further results). (A) CCL11. (B) CCL13. (C) VEGF. (D) TSLP. (E) TNF-α. (F) IL-6. Data were
analysed by Kruskal-Wallis with post-hoc Dunn’s test. IL=interleukin. TNF=tumour necrosis factor. TSLP=thymic
stromal lymphopoietin. CCL=CC chemokine ligand. VEGF=vascular endothelial growth factor.

interferon response proteins, CCL5, CXCL9, and CXCL10,
remained elevated and CXCL11 decreased. Concentrations
of the inflammatory markers IL-1β, IL-33, and IL-6 also
increased over time (figure 3I, appendix p 12), illustrating
persistent inflammation and epithelial damage.
Serum inflammatory mediators up to 35 days after
initial infection remained elevated compared with
healthy controls (figure 4A–F, appendix p 13). These
552

In this study, we examined the inflammatory effect of
SARS-CoV-2 on the upper airway at a very early
timepoint during the course of COVID-19 disease13 and
followed patients over the evolutionary course of
SARS-CoV-2 infection. Our findings show that there is
an early activated and enhanced immune response in
early COVID-19 in the upper airway. We have also
shown that we might be able to predict which patients
will clinically deteriorate, by noting that they have a
blunted interferon and an exagerated CCL24 airway
inflammatory response. This finding has value in the
early identification, monitoring, and therapeutics of
this population by using biomarkers from the nose to
detect the patients who might get worse. We have also
found that there is persistent systemic inflammation in
COVID-19, which can be measured up to 35 days after
the initial infection and past the median time of clinical
recovery. Finally, network analysis has shown that
patterns of inflammation and inflammatory pathways
in the airway and circulation are modified significantly
www.thelancet.com/respiratory Vol 10 June 2022
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Figure 5: Network analysis of mediator correlation data
(A) Modularity maximisation and community detection for eigenvalue-based noise-cleaned nasal mucosal mediator data. (A1) Networks at initial SARS-CoV-2 infection. (A2) Networks after
14 days of initial SARS-CoV-2 infection. (A3) Networks after treatment with inhaled budesonide. Node size indicates eigenvalue centrality and arcs indicate non-zero noise-cleaned correlation.
There are four modules of roughly equal size in each network. A1 and A2 are similar with 72% overlap indicating persistent relationship of inflammation over time. A1 and A3 have 27% overlap (which
would be expected by a chance reassignment of nodes to the four modules) indicating that treatment with inhaled budesonide changes the inflammatory networks entirely. (B) Modularity
maximisation and community detection for eigenvalue-based noise-cleaned serum data in participants from 28 to 35 days following SARS-CoV-2 infection. (B1) Network analysis of serum from
participants in the usual care group. (B2) Network analysis of serum from participants in the budesonide group. The two networks are entirely different in terms of membership with 30% overlap
(equivalent to a random node reassignment to modules). The network analysis shown here suggests that budesonide treatment dramatically rearranged the mediator pathways in serum. CCL=CC
chemokine ligand. CRP=C-reactive protein. CXCL=CXC chemokine ligand. GM-CSF=granulocyte-macrophage colony-stimulating factor. IFN=interferon. IL=interleukin. PDGF=platelet-derived growth
factor. TGF=transforming growth factor. TNF=tumour necrosis factor. TSLP=thymic stromal lymphopoietin. VEGF=vascular endothelial growth factor. vWF=von Willebrand factor.

following treatment with inhaled budesonide. These
findings suggest that inhaled budesonide modulates
the inflammatory pathways in the upper respiratory
tract and circulation following COVID-19 infection
(appendix p 14).
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Due to the nature of the STOIC study13 design, we were
able to examine the kinetics of inflammation between
patients with early COVID-19 and in patients who received
inhaled budesonide as a treatment intervention. We found
that, in early COVID-19, there is upregulation of
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inflammation, which does not return to levels observed in
healthy patients over time. Furthermore, mediators such
as VEGF were found to be lower in the respiratory tract in
early disease as previously found in severe COVID-19.19
Examination of the mediator temporal relationship
showed that there was often a biphasic peak of
inflammatory mediators, which is staggered and persists
over time. Importantly, however, we found that in patients
given inhaled budesonide, the inflammatory peak was
attenuated for TNF-α, GM-CSF, and CCL5, and promoted
for IFN-γ. IFN-γ is an important promoter of anti-viral
immunity20 playing a role in the inhibition of viral
replication in cells,21 suggesting that this is another
mechanism for the efficacy of inhaled corticosteroids.
Following inhaled budesonide treatment, the nasal
mucosal response is different from that of the usual care
group with an anti-inflammatory response (IL-10), an
increase in alarmins (IL-33 and TSLP), and a reduction in
the Th2 inflammatory response, which suggests the
promotion of a normal anti-viral response and suppression
of the exaggerated Th2 inflammatory response.
Our study suggests, unlike previous assumptions,22 that
there is a vigorous and early immune response in the
upper airway in patients who develop COVID-19. This
response, in comparison with healthy controls, is an early
combined type I and type II interferon response, proinflammatory response, and anti-inflammatory response.
Interestingly, early in COVID-19, there is also a Th2
immune response, mediated mainly by CCL11 and IL-4.
This early COVID-19 innate cytokine immune response
leads to recruitment of eosinophils, natural killer cells,
and macrophages, and is an immune response similar to
that observed with other respiratory viruses.23
We have found that, in patients in whom there was a
clinical deterioration following SARS-CoV-2 infection,
the initial inflammatory response in the airway is
blunted with reduced concentrations of IL-2, IL-33,
IL-12, and IFN-α2a, in comparison with patients with
COVID-19 without deterioration. A blunted interferon
response, as a feature of severe COVID-19, has
previously been observed in the systemic circulation24
and from in-vitro cell line transcription expression.25 As
our study focused in early COVID-19, these findings
suggest that an early impaired interferon response to
COVID-19 could indicate a poor prognosis, potentially
offering a strategy for early treatment for this at risk
patient population. The identification of patients early
and at high risk of deterioration could markedly
improve clinical care for patients. Our findings might
also suggest why treatment trials enhancing or
attenuating specific inflammatory mediators might
have larger treatment effects if given early, with an even
greater likelihood of success if targeted to patients with
a biological high risk. Interestingly, CCL24 was the only
mediator that increased in patients who deteriorated
following SARS-CoV-2 infection. The CCL subfamily of
eosinophil chemotactic proteins (CCL11, CCL24, and
554

CCL26), along with IL-5, GM-CSF, and CCL5 are
responsible for lung recruitment and activation of
eosinophils.26 Recruitment of eosinophils to the lung is
the most probable explanation for the reduced
circulatory number of eosinophils observed as part of
the clinical picture of severe COVID-19.27 Furthermore,
inhaled corticosteroids are recognised to be ther
apeutically effective in patients with an eosinophilic
phenotype of airways disease.28 The elevation of CCL24
in patients that subsequently deteriorated from our
study validates that the high eosinophilic phenotype is
associated with severe disease, which is in line with
previously published findings.15
Our study is also the first to show that there is ongoing
inflammation in the circulation, over 4 weeks after
SARS-CoV-2 infection, with elevated concentrations of
IL-2, IL-6, CXCL8, CCL13, TNF-α, CCL11, CCL24, and
CCL26. Persistent symptoms following SARS-CoV-2
infection have been identified as an emerging problem
(long COVID)29 and our study indicates that this issue
might be underlined by persistent inflammation. To note,
the airway and peripheral blood immune profile in severe
COVID-19 is different from early infection.30 It is,
therefore, plausible that the identification of inflammatory
mediators in the systemic circulation is delayed compared
with assessing samples proximal to the site of infection.
The STOIC study showed that persistence of symptoms
was significantly lower in patients given inhaled
budesonide, suggesting that early inhaled corticosteroid
treatment can improve symptoms of COVID-19 and
might help to prevent the effects of long COVID. We
found that TNF-α and CCL11 were significantly lower in
the systemic circulation in patients who had been treated
with inhaled budesonide compared with usual care,
suggesting that these mediators could be key for future
clinical targets, particularly against long COVID.
Interestingly, patients with long COVID commonly
report symptoms of breathlessness,31 and asthma has
been found to be the only pre-existing comorbidity with
an independent association of long COVID.31 Whether
there is a pre-existing host or exaggeration of the
Th2 phenotype that leads to long COVID warrants further
investigation.
Our study provides a unique mechanistic insight into
the host respiratory immune and inflammatory response
to early COVID-19 and following a therapeutic intervention
that has been shown to have clinical benefit in treating
these patients.13,14 Notably, studies thus far have examined
only a small number of airway samples from severe and
hospitalised patients, often late in the disease course32,33 or
measured the immune response in the circulation.34
Moreover, these studies have focussed on transcriptional
analysis, namely gene expression, which might not fully
capture the protein environment. In contrast, our study is
the first to examine protein concentration in the upper
respiratory tract of patients with early COVID-19, thus
providing a mechanistic insight into the host respiratory
www.thelancet.com/respiratory Vol 10 June 2022
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immune and inflammatory response to early COVID-19.
The number of participants studied was based on the
STOIC sample size, calculated for assessment of a clinical
treatment endpoint. Although we did not conduct a formal
sample size for an immunological endpoint, we can
confirm that this analysis was suitably powered and that
for any one single mediator the sample size we have is on
average twice the number needed for an α of 0·05 and a
β of 0·20 (80% power).
Our study has some limitations. Firstly, we did not
obtain daily samples, nor did we obtain samples from the
lower respiratory tract. However, to our knowledge, this is
the first study to evaluate the respiratory tract in early
COVID-19 and it is well recognised that the greatest
abundance of angiotensin-converting enzyme 2 receptors
is in the nasal mucosa35 and thus our findings are relevant
to the primary site of infection. Second, our analysis used
raw mediator concentration data, and not log-transformed
mediator data, which can overestimate the SD. However,
this analysis was performed to avoid overinterpretation.
Furthermore, we could not determine any changes in
CXCL8 between health and early COVID-19 as would be
expected, but this finding is likely to reflect assay
sensitivity because CXCL8 was repeatedly over the limit
of detection, occurring in over one third of healthy control
samples and one half of COVID-19 samples. Third, the
STOIC study was conducted in a community setting in
Oxfordshire (UK) and we recognise that our population
were mainly white, despite our attempts to recruit ethnic
minorities via advertisements and social media in local
minority communities, such as places of worship. We
believe, however, these inflammatory findings are likely
to be independent of ethnicity,36 but acknowledge further
study is warranted. Fourth, our study has focused on
inflammation in early COVID-19 and, therefore, does
not allow the evaluation of severe symptoms and
inflammation. Fifth, only 11 patients met the primary
outcome for the STOIC trial, thus replication of CCL24 as
an early biomarker for deterioration is warranted. Finally,
we note that our healthy control sample size was small, in
comparison to the STOIC sample size, but our evaluation
here was primarily as a comparator. Recruitment of a
bigger sample size of controls was limited due to assay
availability and due to the third national lockdown in
the UK. 21 (15%) of STOIC participants had a history of
past or current (but untreated) asthma, whereas none of
the healthy controls by definition had a respiratory
comorbidity. Although, the absence of respiratory comor
bidities in the healthy controls might be noted as a
limitation, our findings do show that the Th2 response to
SARS-CoV-2 is similar across both individuals with or
without respiratory disease.
To conclude, the initial observation of a significant
under-representation of patients with obstructive lung
disease (asthma and COPD) with severe COVID-19 and
the knowledge that treatment with inhaled corticosteroids
is routinely used to prevent viral exacerbations was the
www.thelancet.com/respiratory Vol 10 June 2022

founding hypothesis for the STOIC trial. We have
observed that the clinical benefit of inhaled budesonide
as treatment in early COVID-19 is a consequence of its
inflammatory modulatory effect. Moreover, our study
supports a potential airway biomarker to detect clinical
deterioration of COVID-19 and possible therapeutic
targets for long COVID.
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